In late-stage Tg-neu tumors, Lov treatment did not alter total numbers of tumor-associated leukocytes (not shown), but selectively enhanced infiltration of cytotoxic CD8+ and to a lesser extent, of CD4+ and double-negative T cells. This evidence concerns the gene ERBB2 and neoplasm.